Back to Portfolio

Memo Therapeutics

Fighting diseases with authentic human-derived monoclonal antibodies

Antibodies are our immune system's most sophisticated weapon against diseases and represent highly promising, but difficult to source therapeutics against a wide range of conditions.

Memo Therapeutics develops a unique platform technology (MemoMABTM) that enables a paradigm shift in the discovery of novel therapeutic antibodies. By utilizing cutting-edge nanoliter reactor technology, the platform increases throughput and efficiency of the discovery process and will allow for the first time capturing complete antibody repertoires of individual organisms (human, animal). It enables extremely cost- and time-efficient discovery of highly relevant therapeutic antibody candidates, increasing probability of success in the subsequent clinical development.


Homepage  LinkedIn    


Memo in the News: 

Four Redalpine companies among the Top 30 Swiss start-ups

Memo Therapeutics Completes First Client Project

Redalpine leads Series A for groundbreaking antibody discovery company